Bris­tol My­ers inks pro­tein de­grad­er deal via Cel­gene team's link to seed-stage biotech

Bris­tol My­ers Squibb is adding to its pro­tein de­grad­er line­up, which al­ready in­cludes the likes of A-Al­pha Bio and Evotec, by link­ing arms with a lit­tle-known biotech that’s been com­mu­ni­cat­ing with the sci­en­tists at Cel­gene for the past few years.

The Big Phar­ma is in­vest­ing in Syn­theX and lay­ing out a $550 mil­lion vi­sion for the Bay Area seed-stage biotech that was just “a sketch on a nap­kin” in Toron­to in 2016, co-founder and CEO Maria Solov­ey­chik told End­points News in a pre­view of the Tues­day morn­ing pact.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER